MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
$105,527K
EPS
$0.54
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Gain on sale of nonfinancial assets
-0 0 0
Total revenues
766,208 874,565 776,133 825,410
Cost of sales
194,999 275,709 140,085 150,090
Research and development
178,796 192,413 409,478 161,308
Selling, general and administrative
258,290 446,207 268,415 232,279
Intangible asset amortization
4,483 4,846 4,847 4,846
Total operating expenses
636,568 919,175 822,825 548,523
Income from operations
129,640 -44,610 -46,692 276,887
Interest income
22,560 19,210 17,854 18,827
Interest expense
14,958 2,778 2,579 2,679
Other income (expense), net
3,961 1,025 5,093 4,833
Income before income taxes
141,203 -27,153 -26,324 297,868
Provision for income taxes
35,676 19,420 4,420 57,336
Net income
105,527 -46,573 -30,744 240,532
Basic EPS
0.55 -0.242 -0.16 1.25
Diluted EPS
0.54 -0.228 -0.16 1.23
Basic Average Shares
192,497,000 192,242,000 192,032,000 191,907,000
Diluted Average Shares
197,671,000 203,979,000 192,032,000 197,091,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
VOXZOGO$219,880K (2.87%↑ Y/Y)VIMIZIM$210,204K (11.61%↑ Y/Y)NAGLAZYME$130,074K (13.81%↑ Y/Y)PALYNZIQ$89,558K (-3.98%↓ Y/Y)BRINEURA$47,104K (16.70%↑ Y/Y)ALDURAZYME$36,742K (-24.98%↓ Y/Y)KUVAN$23,880K (-5.00%↓ Y/Y)ROCTAVIAN$2,636K (-74.92%↓ Y/Y)Product$760,078K (3.46%↑ Y/Y)Royalty And Other$6,130K (-41.62%↓ Y/Y)Total revenues$766,208K (2.83%↑ Y/Y)Income from operations$129,640K (-42.10%↓ Y/Y)Interest income$22,560K (18.66%↑ Y/Y)Total operatingexpenses$636,568K (22.12%↑ Y/Y)Other income(expense), net$3,961K (302.71%↑ Y/Y)Income before incometaxes$141,203K (-40.69%↓ Y/Y)Interest expense$14,958K (422.46%↑ Y/Y)Selling, general andadministrative$258,290K (25.31%↑ Y/Y)Cost of sales$194,999K (28.66%↑ Y/Y)Research and development$178,796K (12.64%↑ Y/Y)Intangible assetamortization$4,483K (-7.51%↓ Y/Y)Net income$105,527K (-43.17%↓ Y/Y)Provision for income taxes$35,676K (-31.92%↓ Y/Y)

biomarin-logo-svg

BIOMARIN PHARMACEUTICAL INC (BMRN)

biomarin-logo-svg

BIOMARIN PHARMACEUTICAL INC (BMRN)